A Phase II Study of the HSP Inhibitor STA-9090 in Metastatic Ocular Melanoma
Phase of Trial: Phase II
Latest Information Update: 04 Jul 2018
At a glance
- Drugs Ganetespib (Primary)
- Indications Uveal melanoma
- Focus Therapeutic Use
- 25 Jun 2018 Status changed from active, no longer recruiting to completed.
- 30 Jan 2018 Planned End Date changed from 1 Jun 2017 to 1 Jun 2019.
- 04 Jan 2017 Planned End Date changed from 1 Jan 2017 to 1 Jun 2017.